Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Average PT from Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given a consensus rating of “Buy” by the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $11.71.

A number of equities analysts have recently commented on the company. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Tuesday, May 13th. Benchmark lowered their price target on Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Finally, HC Wainwright assumed coverage on Humacyte in a research note on Wednesday, May 14th. They set a “buy” rating and a $4.00 price target on the stock.

Humacyte Stock Performance

Humacyte stock opened at $2.49 on Friday. The business’s 50-day simple moving average is $1.81 and its 200-day simple moving average is $3.44. The firm has a market capitalization of $386.25 million, a PE ratio of -1.86 and a beta of 1.64. Humacyte has a 52 week low of $1.15 and a 52 week high of $9.97.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.46 million. Research analysts forecast that Humacyte will post -1.27 earnings per share for the current year.

Insider Activity at Humacyte

In related news, Director Kathleen Sebelius acquired 50,000 shares of the firm’s stock in a transaction on Tuesday, April 8th. The shares were bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the acquisition, the director now owns 91,207 shares of the company’s stock, valued at $120,393.24. This trade represents a 121.34% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Dale A. Sander acquired 20,000 shares of the firm’s stock in a transaction on Thursday, April 10th. The shares were bought at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,600 shares of the company’s stock, valued at approximately $62,118. This represents a 97.09% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 83,993 shares of company stock worth $118,224 over the last three months. Company insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Institutional investors have recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. acquired a new stake in Humacyte during the fourth quarter valued at approximately $50,000. Petros Family Wealth LLC acquired a new position in shares of Humacyte in the 4th quarter worth approximately $50,000. Syon Capital LLC acquired a new position in shares of Humacyte in the 4th quarter worth approximately $54,000. Brookstone Capital Management acquired a new position in shares of Humacyte in the 4th quarter worth approximately $56,000. Finally, ACT Wealth Management LLC acquired a new position in shares of Humacyte in the 4th quarter worth approximately $57,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.